Get the Stockscreener App
5.66
0.09%
0.005
After Hours:
5.66
Shattuck Labs Inc stock is traded at $5.66, with a volume of 2.49M.
It is up +0.09% in the last 24 hours and down -12.92% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$5.655
Open:
$5.56
24h Volume:
2.49M
Relative Volume:
2.07
Market Cap:
$568.06M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-7.3155
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
-17.25%
1M Performance:
-12.92%
6M Performance:
-19.37%
1Y Performance:
+136.82%
1-Day Range:
$5.42
$5.885
1-Week Range:
$5.42
$7.09
52-Week Range:
$1.70
$8.33
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
5.66 | 609.20M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
503.25 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
197.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
739.57 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.63 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.12 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Wedbush Lifts Price Target on Shattuck Labs to $14 From $11, Keeps Outperform Rating - marketscreener.com
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development - Investing News Network
Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa - Investing.com Nigeria
Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug - marketscreener.com
Shattuck plans a trial of its drug in about 150 people with moderate-to-severe skin disease - Stock Titan
Preferred dividends of Shattuck Labs, Inc. – DUS:82S - TradingView
Shattuck Labs, Inc.(NasdaqGS: STTK) added to S&P Biotechnology Select Industry Index - marketscreener.com
Shattuck Labs, Inc.(NasdaqGS: STTK) added to S&P Global BMI Index - marketscreener.com
Shattuck Labs Q2 2026 Earnings: Clinical-Stage Balance Sheet in Focus as EPS Meets EstimatesEarnings Whisper Number - dars.gov.et
Return on invested capital % of Shattuck Labs, Inc. – TRADEGATE:82S - TradingView
Taxes of Shattuck Labs, Inc. – TRADEGATE:82S - TradingView
Shattuck Labs at Wells Fargo conference: DR3 bet takes center stage - Investing.com Canada
Shattuck Labs at Wells Fargo conference: DR3 bet takes center stage By Investing.com - Investing.com South Africa
SHATTUCK LABS STOCK : BIG PRICE RECOVERY | STTK STOCK Darpa Autonomous Drone Swarms (RwCs7APen5) - Mshale
Shattuck Labs Announces Participation in Upcoming September Investor Conferences - Investing News Network
Shattuck Labs (STTK) Gains 2.81% to $7.06 as Momentum Builds Above Key SupportBlock Trade Flow - dars.gov.et
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom - Seeking Alpha
STTK Q2 2026 Earnings: Fractional EPS Miss Triggers 6.67% Selloff in Clinical-Stage BiotechUpward Estimate Revision - vinanet.vn
Raymond James Initiates Coverage on Shattuck Labs With Strong Buy Rating, $18 Price Target - marketscreener.com
Raymond James initiates Shattuck Labs stock with strong buy rating By Investing.com - Investing.com India
Raymond James initiates Shattuck Labs stock with strong buy rating - Investing.com
Shattuck (STTK) EPS and Revenue: The EPS Result Is Above Expectation at the Close; Share Response: Shares Move 3.86% Up for the Current SessionEarnings Expansion Phase - vinanet.vn
Shattuck (STTK) Momentum: Records a 3.86% Increase to $7.53 in the Latest Reading; Level Watch: the $7.15 to $7.91 Range Remains in Focus in the Latest SessionSweep Order Flow - vinanet.vn
Shattuck Labs expects ~$59.4M proceeds from exercised warrants - scanx.trade
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Shattuck (STTK) Results Snapshot: EPS Clears the Reported Estimate in Latest Trading; Reported Share Move: Shares Finish 0.81% Higher in the Latest SessionEarnings Preview - vinanet.vn
Weekly Recap: SL-325 Phase 2b Crohn’s trial and Q2 loss, $208.3M cash - TradingView
Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen - MarketBeat
T. Rowe Price Investment Management (STTK) reports 15.3% stake in Shattuck Labs - Stock Titan
Several Insiders Invested In Shattuck Labs Flagging Positive News - webull.com
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade - Yahoo Finance
A Quick Look at Today's Ratings for Shattuck Labs(STTK.US), With a Forecast Between $11 to $18 - Moomoo
Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Shattuck Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion - Investing.com
Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone - TipRanks
Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis - GuruFocus
Shattuck Labs, Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 108% Upside - TradingView
West Tower Group, LLC's Shattuck Labs Inc(STTK) Holding History - GuruFocus
Shattuck Labs, Inc. Stock 12‑Month Price Target Raised to $15.43, Implies 116% Upside - TradingView
STTK Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00 - MarketBeat
Shattuck Labs Raises Cash Reserves to $208.3 Million, Extending Runway to 2029 - Minichart
Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations - MarketBeat
Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count - Kalkine Media
Shattuck Labs Q2 Results: EPS misses estimate, losses widen 50% YoY - scanx.trade
Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases - Bitget
Form 8K Shattuck Labs Inc For: 11 August By Investing.com - Investing.com South Africa
Why is Shattuck Labs stock slipping today? By Investing.com - Investing.com Canada
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Option Exercise |
3.57 |
410 |
1,464 |
86,790 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Sale |
7.01 |
410 |
2,874 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Option Exercise |
3.57 |
23,365 |
83,413 |
109,745 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Option Exercise |
3.57 |
100 |
357 |
86,480 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Sale |
7.08 |
23,365 |
165,424 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Sale |
7.07 |
100 |
707 |
86,380 |
| Pandite Arundathy N. | Chief Medical Officer |
Jun 30 '26 |
Sale |
7.01 |
30,000 |
210,300 |
136,219 |
3.35%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):